Jupiter Asset Management Ltd. Buys Shares of 99,605 GoodRx Holdings, Inc. (NASDAQ:GDRX)

Jupiter Asset Management Ltd. bought a new stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 99,605 shares of the company’s stock, valued at approximately $707,000.

Several other hedge funds have also recently added to or reduced their stakes in GDRX. Citigroup Inc. increased its position in shares of GoodRx by 301.7% during the 3rd quarter. Citigroup Inc. now owns 7,997 shares of the company’s stock valued at $45,000 after purchasing an additional 6,006 shares during the period. Vanguard Group Inc. boosted its position in shares of GoodRx by 2.1% in the third quarter. Vanguard Group Inc. now owns 8,681,111 shares of the company’s stock worth $48,875,000 after buying an additional 177,961 shares during the period. Raymond James & Associates acquired a new stake in shares of GoodRx in the fourth quarter worth $192,000. Assenagon Asset Management S.A. boosted its position in shares of GoodRx by 7.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,349,800 shares of the company’s stock worth $9,044,000 after buying an additional 99,072 shares during the period. Finally, International Assets Investment Management LLC acquired a new stake in GoodRx during the fourth quarter valued at $115,000. Institutional investors own 63.77% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Barclays lifted their price objective on GoodRx from $9.00 to $10.00 and gave the company an “overweight” rating in a research report on Monday, May 20th. Morgan Stanley lifted their price objective on GoodRx from $7.00 to $9.50 and gave the company an “equal weight” rating in a research report on Monday, June 10th. Royal Bank of Canada raised GoodRx from a “sector perform” rating to an “outperform” rating and lifted their price objective for the company from $8.00 to $10.00 in a research report on Thursday, May 23rd. TD Cowen boosted their price target on GoodRx from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, May 16th. Finally, Wells Fargo & Company raised GoodRx from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $7.50 to $10.00 in a research report on Monday, March 25th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.32.

GoodRx Price Performance

Shares of GDRX stock traded up $0.44 during trading hours on Friday, hitting $8.50. The company had a trading volume of 1,186,534 shares, compared to its average volume of 981,014. The firm has a market capitalization of $3.19 billion, a price-to-earnings ratio of -850.00, a PEG ratio of 3.96 and a beta of 1.39. The company has a debt-to-equity ratio of 1.02, a quick ratio of 6.29 and a current ratio of 6.29. GoodRx Holdings, Inc. has a 12 month low of $4.14 and a 12 month high of $9.37. The firm’s fifty day moving average is $7.89 and its 200 day moving average is $7.14.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Thursday, May 9th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.01). The business had revenue of $197.88 million during the quarter, compared to analyst estimates of $196.20 million. GoodRx had a positive return on equity of 3.45% and a negative net margin of 0.86%. On average, sell-side analysts predict that GoodRx Holdings, Inc. will post 0.17 EPS for the current fiscal year.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.